Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
LONDON - Futura Medical (TASE:BLWV) plc (AIM:FUM), a consumer healthcare company specializing in sexual health products, announced Friday that it is unaware of any reason for the recent increase in its share price.
In a statement to investors, the company’s board indicated that apart from previously announced board changes and the proposed appointment of Alex Duggan as Interim CEO on July 8, it knows of no explanation for the stock movement.
The company, which develops and commercializes sexual health products including its lead product Eroxon, made the clarification through a regulatory news service announcement to the London Stock Exchange (LON:LSEG).
Eroxon is an over-the-counter topical gel treatment for erectile dysfunction that the company states helps men get an erection in ten minutes.
Futura Medical has established distribution partnerships in several major markets, including with Haleon in the United States and Cooper Consumer Health in Europe.
The statement was issued by Angela Hildreth, Finance Director and Chief Operating Officer of the company.
Futura Medical’s shares are traded on the AIM market of the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.